![]() Patients who took the drug for this ailment where severely harmed and many even died. If that's not cause for legal action, Abilify's manufacturer has already paid $515 million in settlement fees to the federal government based on charges accusing the company of illegal marketing to older patients suffering from dementia. Just like Abilify, Mirapex's manufacturer failed to warn about the risks when taking the drug. In 2010, a jury made Boehringer Ingelheim pay the officer $8.3 million dollars, including punitive damages. Boehringer Ingelheim, Charbonneau who is a retired police officer filed a lawsuit against the manufacturer after losing $260,000 to compulsive gambling that lasted several years on the Mirapex. Just like Abilify, Mirapex affects the D3 receptor controlling the emotions and pleasure potential of patients. More specifically, Mirapex which is used for Parkinson's disease has been called into question due to a link between compulsive gambling and the drug. In past lawsuits regarding compulsive behavior after taking a drug, the patient has won due to the unmentioned risk. Several cases involved with the drug have already pursued Ostuka for outstanding side effects. Regardless of who is taking the drug for whatever disorder, Abilify's risks have impaired many participants' lives. ![]() So why should I care? This is another instance of off-labeling by a drug company who markets their particular drug for multiple causes in expectation of a higher profit margin. In people with mental disorders, these systems are stimulated excessively, or not enough. These neurotransmitters regulate mood and behavior. Researchers have linked the compulsive behavior to the over-stimulated (D3) receptors or dopamine 3 receptors that at a normal level, keep the dopamine system working in response to a particular activity such as eating and other things we need to survive. Off Label Usage of Abilify without Proper Safety Warningįor adults using the drug, Abilify has become associated with compulsive behavior such as gambling, hypersexuality and eating. After extended use, the problems associated with the drug increase. The researchers distinguished that the use of these medications for non-psychosis-related disorders in children now accounts for the bulk of prescriptions. While earlier studies have recognized the connection among antipsychotics and diabetes, this latest study is the first large, well-designed revision to look at the hazard in pediatric patients. In August 2013, researchers at Vanderbilt University, the Mayo Clinic and Columbia University published a study which found that children who consume different antipsychotic drugs like Abilify contain a threefold increased risk of developing type 2 diabetes. ![]() Researchers have been able to link Abilify to not only type 2 diabetes in children but also compulsive behavior in adults. Unfortunately, there have been a climbing number of participants who have experienced one of the severe side effects that cause stress for not only their physical well-being but also their mental state. In all cases, the expected outcome from taking the medication is to help these individuals lead more stable lives. ![]() Recently, Otsuka received exclusive rights to market the drug for children with Tourettes syndrome. The FDA approved the drug to treat different psychiatric disorders including schizophrenia, bipolar disorder and major depression. In fact the company who manufactures the drug, Otsuka has earned revenue of $4.9 billion in 2014. Abilify is a top-selling antipsychotic prescription in the United States.
0 Comments
Leave a Reply. |